Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · colon-landscapes@1

SRR15030843

—

57e4ed1b-d65e-50b5-8b75-1f0b16fdd737

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
—

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • COAGULATION+0.630
  • EPITHELIAL_MESENCHYMAL_TRANSITION+0.600
  • XENOBIOTIC_METABOLISM+0.540
  • ANGIOGENESIS+0.480
  • FATTY_ACID_METABOLISM+0.420
  • BILE_ACID_METABOLISM+0.410
  • APICAL_SURFACE+0.360
  • ADIPOGENESIS+0.340
  • COMPLEMENT+0.340
  • OXIDATIVE_PHOSPHORYLATION+0.340

Top 10 suppressed

  • MYC_TARGETS_V2-0.330
  • MITOTIC_SPINDLE-0.320
  • WNT_BETA_CATENIN_SIGNALING-0.290
  • G2M_CHECKPOINT-0.280
  • E2F_TARGETS-0.270
  • PI3K_AKT_MTOR_SIGNALING-0.210
  • INTERFERON_ALPHA_RESPONSE-0.180
  • UNFOLDED_PROTEIN_RESPONSE-0.150
  • DNA_REPAIR-0.140
  • MYC_TARGETS_V1-0.120

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

10 twins match this tumor's tissue · 0 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1TCGA-BH-A0HF-01A-11R-A056-07
breast-umap@18
—A0.924
2TCGA-AN-A03X-01A-21R-A00Z-07
breast-umap@18
—A0.881
34c075dfa-f213-4e97-9c4e-6aac7b8345c7
melanoma-umap@29
——0.875
4s0099997
melanoma-umap@29
——0.864
5TCGA-BH-A0AY-01A-21R-A00Z-07
breast-umap@18
—A0.860
620040010.TNBC
breast-umap@18
—F0.848
7SRR8518353
breast-umap@18
—F0.847
8TCGA-21-5784-01A-01R-1635-07
lung-landscapes@6
—cohortSQ10.834
9830ff04e-ebca-42d8-a018-0a49315640b5
colon-landscapes@1
——0.831
10TCGA-56-7731-01A-11R-2125-07
lung-landscapes@6
—cohortSQ10.827

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 37 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
COAGULATION0.630Binimetinib— uncovered
EPITHELIAL_MESENCHYMAL_TRANSITION0.600Inavolisib— uncovered
XENOBIOTIC_METABOLISM0.540Inavolisib— uncovered
ANGIOGENESIS0.480Remibrutinib— uncovered
FATTY_ACID_METABOLISM0.420Inavolisib— uncovered
BILE_ACID_METABOLISM0.410Inavolisib— uncovered
APICAL_SURFACE0.360Temsirolimus— uncovered
ADIPOGENESIS0.340Inavolisib— uncovered
COMPLEMENT0.340Inavolisib— uncovered
OXIDATIVE_PHOSPHORYLATION0.340Remibrutinib— uncovered
ESTROGEN_RESPONSE_EARLY0.320Inavolisib— uncovered
GLYCOLYSIS0.320Inavolisib— uncovered
INFLAMMATORY_RESPONSE0.310Idelalisib— uncovered
REACTIVE_OXYGEN_SPECIES_PATHWAY0.310Inavolisib— uncovered
ESTROGEN_RESPONSE_LATE0.290Idelalisib— uncovered
MYOGENESIS0.290Inavolisib— uncovered
ANDROGEN_RESPONSE0.270Inavolisib— uncovered
APICAL_JUNCTION0.260Inavolisib— uncovered
TGF_BETA_SIGNALING0.250Inavolisib— uncovered
KRAS_SIGNALING_UP0.230Inavolisib— uncovered